Posted Oct. 5, 2012 at 7:20 a.m.
Research Triangle Park, N.C. — Universities and small pharmas used to be able to reach deals where a pharmaceutical company would buy an early stage asset lock, stock and barrel. But the de-risking trend means that Big Pharma aims to structure deals in a way that pushes more risk onto the licensor. The payoff comes at the back-end of a deal -- if and when a technology reaches development and commercialization milestones....
Risk-averse Big Pharma just saying 'No' to small drug firm deals
Post a comment
Print this blog postE-mail blog post
Share
Research Triangle Park, N.C. — Universities and small pharmas used to be able to reach deals where a pharmaceutical company would buy an early stage asset lock, stock and barrel. But the de-risking trend means that Big Pharma aims to structure deals in a way that pushes more risk onto the licensor. The payoff comes at the back-end of a deal -- if and when a technology reaches development and commercialization milestones....
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 WRAL Tech Wire. All rights reserved.Please log in or register to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
The Skinny
Duke's Vivek Wadhwa cracks Time 'Most Influential' list
IBM layoff update: North American cuts climb; mum is word down under
At last! Sprint 4G service formally launches in Triangle
Big Blue's layoff total climbs in RTP; North America total surges past 2,800
Big Blue layoff count nears 2,800 in North America alone
NC's high-tech job picture improves in May, but ...
IBM layoff count hits nearly 2,300 across 31 work groups
NC IDEA: Startup deal flow 'better than it has ever been'
IBM's job cuts are global, nearing 4,000; most are in U.S.
CEO fears for future of NC Biofuels Center due to budget cuts













